Biomarker study using cell-free DNA from lEGFR T790M-positive ung adenocarcinoma patients who receive osimertinib + ramucirumab after EGFR-TKI failure
Not Applicable
- Conditions
- lung adenocarcinoma
- Registration Number
- JPRN-UMIN000035642
- Lead Sponsor
- Eli Lilly
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concordance between tumor tissue and cell-free DNA
- Secondary Outcome Measures
Name Time Method